Biochem/physiol Actions

Reversible: no

Product does not compete with ATP.

Primary TargetJNK

Cell permeable: yes

General description

A cell-permeable 37 amino acid peptide constructed by fusing the JNK binding domain sequence (δ) (amino acids 33-57) of human c-Jun to the HIV-TAT transduction domain sequence (amino acids 47-57) with a γ-aminobutyric acid (GABA) spacer. Reported to specifically disrupt c-Jun/JNK complex formation and subsequent phosphorylation and activation of c-Jun by JNK in vitro and in intact cells. Also reported to induce apoptosis in HeLa cells. Mode of inhibition is distinct from that of JNK Inhibitor II (SP600125; Cat. No. 420119), so may complement this inhibitor in JNK pathway studies.

A cell-permeable 37-mer peptide constructed by fusing human c-Jun δ domain (amino acids 33-57) sequence with that of HIV-TAT protein transduction domain (amino acids 47-57) via a γ-aminobutyric acid (GABA) spacer. Shown to specifically disrupt c-Jun/JNK complex formation and the subsequent phosphorylation and activation of c-Jun by JNK both in vitro and in intact cells. Since its mode of inhibition is different than that of JNK Inhibitor II (SP600125; Cat. No. 420119), these two inhibitors can complement each other in JNK signaling pathway studies.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Holzberg, D., et al. 2003. J. Biol. Chem.278, 40213.

Packaging

1 mg in Plastic ampoule

Packaged under inert gas

Physical form

Supplied as a trifluoroacetate salt.

Reconstitution

Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Sequence

Ac-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-gaba-Ile-Leu-Lys-Gln-Ser-Met-Thr-Leu-Asn-Leu-Ala-Asp-Pro-Val-Gly-Ser-Leu-Lys-Pro-His-Leu-Arg-Ala-Lys-Asn-NH₂

Warning

Toxicity: Carcinogenic / Teratogenic (D)